Vitamin D and breast cancer in women


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Recent investigations have revealed an association of vitamin D deficiency with a wide spectrum of diseases, such as cardiovascular diseases, depression, diabetes mellitus, Alzheimer’s disease, and different types of cancer. Numerous studies have established a direct relationship between low vitamin D levels and breast cancer incidence, a risk for distant metastases and overall survival rates. Clinical and experimental findings have shown the implication of not only of the absolute concentration of vitamin D, but also the regulatory effect of vitamin D and major enzymes governing its local metabolism. Vitamin D receptor gene polymorphism and different expression of enzymes involved in the synthesis of the biologically active form of vitamin D and in the catabolism of the vitamin finally determine the local concentration of vitamin D. The latter in turn controls cell proliferation in the breast, which is the basis for its benign and malignant lesions. Examining the specific features of the effect of vitamin D on breast tissue in health and disease allows correction of vitamin D deficiency to be regarded as one of the effective methods for primary prevention of breast cancer.

Full Text

Restricted Access

About the authors

L. I Maltseva

Kazan State Medical Academy, Ministry of Health of the Russian Federation

Email: laramalc@mail.ru
Doctor of Medicine, Professor, Head of Department of Obstetrics and Gynecology № 1

Yu. V Garifullova

Kazan State Medical Academy, Ministry of Health of the Russian Federation

Email: gamgg@yandex.ru
post-graduate of Department of Obstetrics and Gynecology № 1

References

  1. Institute of Medicine, Food and Nutrition Board. Dietary reference intakes for calcium and vitamin D. Washington, DC: National Academy Press; 2010.
  2. Bischoff-Ferrari H.A., Burckhardt P., Quack-Loetscher K., Gerber B., I’Allemand D., Laimbacher J., Bachmann M., Rizzoli R. Vitamin D deficiency: evidence, safety, and recommendations for the Swiss population. Report written by a group of experts on behalf of the Federal Commission for Nutrition (FCN). 2012. Available at: http://www.iccidd.org/p142000804. html. 3.
  3. Dawson-Hughes B., Mithal A., Bonjour J.P., Boonen S., Burckhardt P., Fuleihan G.E. et al. IOF position statement: vitamin D recommendations for older adults. Osteoporos. Int. 2010; 21(7): 1151-4.
  4. Elamin M.B., Abu Elnour N.O., Elamin K.B., Fatourechi M.M., Alkatib A.A., Almandoz J.P. et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2011; 96 (7): 1931-42.
  5. Howland R.H. Vitamin D and depression. J. Psychosoc. Nurs. Ment. Health Serv. 2011; 49(2): 15-8.
  6. Lenders C.M., Feldman H.A., Von Scheven E., Merewood A., Sweeney C., Wilson D.M. et al. Relation of body fat indexes to vitamin D status and deficiency among obese adolescents. Am. J. Clin. Nutr. 2009; 90(3): 459-67.
  7. Littlejohns T.J., Henley W.E., Lang I.A., Annweiler C., Beauchet O., Chaves P.H. et al. Vitamin D and the risk of dementia and Alzheimer disease. Neurology. 2014; 83(10): 920-8.
  8. Mitri J., PittasA.G. Vitamin D and diabetes. Endocrinol. Metab. Clin. North Am. 2014; 43(1): 205-32.
  9. OoinL.L., Zhou H., KalaknnR., Zheng Y., ConigravenA.D., SeibelnM.J., Dunstan C.R. Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis. Cancer Res. 2010; 70(5): 1835-44.
  10. Garland C., Garland F., Gorham E. Epidemiology ofcancer risk and vitamin D. In: Holick M., ed. Vitamin D: molecular biology, physiology, and applications. Totowa, New Jersey: Humana Press; 1999: 375-409.
  11. John E.M., Schwartz G.G., Dreon D.M., Koo J. Vitamin D and breast cancer risk: the NHANES I Epidemiologic follow-up study, 1971-1975 to 1992. National Health and Nutrition Examination Survey. Cancer Epidemiol. Biomarkers Prev. 1999; 8(5): 399-406.
  12. Gorham E.D., Garland C.F, Garland F.C. Acid haze air pollution and breast and colon cancer in 20 Canadian cities. Can. J. Public Health. 1989; 80(2): 96-100.
  13. GarlandnF.C., Garland C.F, Gorham E.D., Young J.F. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev. Med. 1990; 19(6): 614-22.
  14. Garland C.F., Gorham E.D.,Mohr S.B., Grant W.B., Giovannucci E.L., Lipkin M. et al. Vitamin D and prevention of breast cancer: pooled analysis. J. Steroid Biochem. Mol. Biol. 2007; 103(3-5): 708-11.
  15. Rejnmark L., Tietze A., Vestergaard P., Buhl L., Lehbrink M., Heickendorff L., Mosekilde L. Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case-control study. Cancer Epidemiol. Biomarkers Prev. 2009; 18(10): 2655-60.
  16. Toner C.D., Davis C.D., John A. Milner J.A. The vitamin D and cancer conundrum: aiming at a moving target. J. Am. Diet. Assoc. 2010; 110(10): 1492-500.
  17. Goodwin P.J., Ennis M., Pritchard K.I., Koo J., Hood N. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J. Clin. Oncol. 2009; 27(23): 3757-63.
  18. Colston K.W. Vitamin D and breast cancer risk. Best Pract. Res. Clin. Endocrinol. Metab. 2008; 22(4): 587-99.
  19. Zinser G.M., Suckow M., Welsh J. Vitamin D receptor (VDR) ablation alters carcinogen-induced tumorigenesis in mammary gland, epidermis and lymphoid tissues, J. Steroid Biochem. Mol. Biol. 2005; 97(1-2): 153-64.
  20. McCullough M.L., Bostick R.M., Mayo T.L. Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu. Rev. Nutr. 2009; 29: 111-32.
  21. Raimondi S., Johansson H., Maisonneuve P., Gandini S. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis. 2009; 30(7): 1170-80.
  22. Tang C., Chen N., Wu M., Yuan H., Du Y. Fok1 polymorphism of vitamin D receptor gene contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res. Treat. 2009; 117(2): 391-9.
  23. Colin E.M., Weel A.E., Uitterlinden A.G., Buurman C.J., Birkenhäger J.C., Pols H.A., van Leeuwen J.P. Consequences of vitamin D receptor gene polymorphisms for growth inhibition of cultured human peripheral blood mononuclear cells by 1, 25-dihydroxyvitamin D3. Clin. Endocrinol. (Oxford). 2000; 52(2): 211-6.
  24. Uitterlinden A.G., Fang Y., Van Meurs J.B., Pols H.A., Van Leeuwen J.P. Genetics and biology of vitamin D receptor polymorphisms. Gene. 2004; 338(2): 143-56.
  25. Mehta R.G., Peng X., Alimirah F., Murillo G., Mehta R. Vitamin D and breast cancer: emerging concepts. Cancer Lett. 2013; 334(1): 95-100.
  26. Dalessandri K.M., Miike R., Wiencke J.K., Farren G., Pugh T.W., Manjeshwar S. et al. Vitamin D receptor polymorphisms and breast cancer risk in a high-incidence population: a pilot study. J. Am. Coll. Surg. 2012; 215(5): 652-7.
  27. Lundin A.C., Soderkvist P., Eriksson B., Bergman-Jungestrom M., Wingren S. South-East Sweden Breast Cancer Group. Association of breast cancer progression with a vitamin D receptor gene polymorphism. Cancer Res. 1999; 59(10): 2332-4.
  28. Lowe L.C., Guy M., Mansi J.L., Peckitt C., Bliss J., Wilson R.G., Colston K.W. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotypes and breast cancer risk in a UK Caucasian population. Eur. J. Cancer. 2005; 41(8): 1164-9.
  29. Lopes N., Sousa B., Martins D., Gomes M., Vieira D., Veronese L.A. et al. Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions.BMC Cancer. 2010, 10: 483. Available at: http://www.biomedcentral.com/1471-2407/10/483
  30. Fillenberg S., Johanna L., Loreen R., Schmidmayr M., Artmann A., Kiechle M., Seifert-Klauss V. Vitamin D and breast density in pre- and postmenopausal women. In: 9th European Congress on Menopause and Andropause. Athens Greece, 28-31 March, 2012. Maturitas. 2012; 71(Suppl.1): S1-82.
  31. Sprague B.L., Trentham-Dietz A., Gangnon R.E., Buist D.S., Burnside E.S., Aiello Bowles E.J. et al. The vitamin D pathway and mammographic breast density among postmenopausal women. Breast Cancer Res. Treat. 2012; 131(1): 255-65. doi: 10.1007/s10549-011-1726-5.
  32. Bérubé S., Diorio C., Mâsse B., Hébert-Croteau N., Byrne C., Côté G. et al. Vitamin D and calcium intakes from food or supplements and mammo-graphic breast density. Cancer Epidemiol. Biomarkers Prev. 2005; 14(7): 1653-9.
  33. Simpson E.R. Sources of estrogen and their importance. J. Steroid Biochem. Mol. Biol. 2003; 86(3-5): 225-30.
  34. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm. IGF Res. 2003; 13(4): 113-70.
  35. Swami S., Krishnan A.V., Feldman D. 1alpha, 25-Dihydroxyvitamin D3 downregulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Clin. Cancer Res. 2000; 6(8): 3371-9.
  36. Bouvard B., Annweiler C., Sallé A., Beauchet O., Chappard D., Audran M., Legrand E. Extraskeletal effects of vitamin D: Facts, uncertainties, and controversies Joint Bone Spine. 2011; 78(1): 10-6.
  37. Chlebowski R.T. Nutrition and physical activity influence on breast cancer incidence and outcome. The Breast. 2013; 22(Suppl.2): S30-7.
  38. Lappe J.M., Travers-Gustafson D., Davies K.M., Recker R.R., Heaney R.P. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am. J. Clin. Nutr. 2007; 85(6): 1586-91.
  39. Zeichner S.B., Koru-Sengul T., Shah N., Liu Q., Markward N.J., Montero A.J. et al. mproved clinical outcomes associated with vitamin D supplementation during adjuvant chemotherapy in patients with HER2+ nonmetastatic breast cancer. Clin. Breast Cancer. 2015; 15(1): e1-11.
  40. Maalmi H., Ordönez-Mena J.M., Schöttker B., Brenner H. Serum 25-hydroxyvitamin D levels and survival in colorectal and breast cancer patients: systematic review and meta-analysis of prospective cohort studies. Eur. J. Cancer. 2014; 50(8): 1510-21.
  41. Buttigliero C., Monagheddu C., Petroni P., Saini A., Dogliotti L., Ciccone G., Berruti A. Prognostic role of vitamin D status and efficacy of vitamin D supplementation in cancer patients: a systematic review. Oncologist. 2011; 16(9): 1215-27.
  42. Piura E., Chapman J.W, Lipton A., Zhu L., Leitzel K., Wilson C.F. et al. Serum 1-OH vitamin D and prognosis of postmenopausal breast cancer patients: NCIC-CTG MA 14 trial. J. Clin. Oncol. 2009; 27(Suppl.): A-534, 15s.
  43. Hansen C.M., Frandsen T.L., Brunner N., Binderup L. 1 alpha,25-dihy-droxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. Clin. Exp. Metastasis. 1994; 12(3): 195-202.
  44. Sundaram S., Beckman M.J., Bajwa A., Wei J., Smith K.M., Posner G.H., Gewirtz D.A. QW-1624F2-2, a synthetic analogue of 1,25-dihydroxyvitamin D3, enhances the response to other deltanoids and suppresses the invasiveness of human metastatic breast tumor cells. Mol. Cancer Ther. 2006; 5(11): 2806-14.
  45. El Abdaimi K., Dion N., Papavasiliou V., Cardinal P.E., Binderup L., Goltzman D. et al. The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res. 2000; 60(16): 4412-8.
  46. Yamamoto N., Suyama H., Yamamoto N., Ushijima N. Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF). Int. J. Cancer. 2008; 122(2): 461-7.
  47. Oikawa T., Hirotani K., Ogasawara H., Katayama T., Nakamura O., Iwaguchi T., Hiragun A. Inhibition of angiogenesis by vitamin D3 analogues. Eur. J. Pharmacol. 1990; 178(2): 247-50.
  48. Mantell D.J., Owens P.E., Bundred N.J., Mawer E.B., Canfield A.E. 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ. Res. 2000; 87(3): 214-20.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies